Dosing information for epilepsy
STAVZOR is indicated for monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures.
STAVZOR is also indicated for adjunctive therapy in patients with multiple seizure types that include absence seizures.
Dosage forms and strengths
STAVZOR is available in 125 mg, 250 mg and 500 mg dosage strengths, making it convenient to initiate and titrate.
Dosage and administration
Target serum levels for epilepsy dosing are 50-100 µg/mL.
Adjunctive therapy, initial monotherapy and conversion to monotherapy dosing
Initial dose: 10 to 15 mg/kg/day
Titration: Increase by 5 to 10 mg/kg/week to achieve optimal clinical response
Optimal clinical response: Optimal clinical response is usually achieved at daily doses below 27.2 mg/lb/day (60 mg/kg/day).
- If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 to 100 µg/mL).
Total daily doses: Total daily doses that exceed 250 mg should be given in divided doses.
Conversion to monotherapy: Please see full STAVZOR Prescribing Information
Administration
Complex Partial Seizures: Start at 10 to 15 mg/kg/day, increasing at one week intervals by 5 to 10 mg/kg/day to achieve optimal clinical response. If response is not satisfactory, check valproate plasma level.
Absence Seizures: Start at 15 mg/kg/day, increasing at one week intervals by 5 to 10 mg/kg/day until seizure control or limiting side effects.
Converting from other formulations of Depakene®
Initiate STAVZOR, as replacement therapy, at the same daily dose and dosing schedule as the patient's previous formulation.
After the patient is stabilized on STAVZOR, a dosing schedule of 2 or 3 times a day may be elected in selected patients on Depakene.
- For more information please see full STAVZOR Prescribing Information
Depakene (divalproex sodium) is a registered trademark of Abbott Laboratories, North Chicago, IL.
